Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine

G. Northoff, J. Eckert, J. Fritze

研究成果: 雜誌貢獻文章同行評審

90 引文 斯高帕斯(Scopus)

摘要

Therapeutic efficacy of the NMDA antagonist amantadine is reported in three acute neuroleptic free akinetic catatonic patients. Intravenous infusion of amantadine led to the resolution of catatonic symptoms and considerable reductions of scores in various motor scales (Simpson Angus scale for extrapyramidal side effects (SEPS), the abnormal involuntary movement scale (AIMS), Rogers catatonia and schizophrenia scales). The therapeutic effect of amantadine showed a characteristic temporal pattern with most pronounced effects four to six hours after administration and recurrence of catatonic symptoms by 24 hours later, at least partially. Such a temporal pattern of therapeutic efficacy and decreasing efficacy occurred in all three patients on all days. The results suggest the central importance of glutamatergic dysfunction in catatonic syndrome.
原文英語
頁(從 - 到)404-406
頁數3
期刊Journal of Neurology, Neurosurgery and Psychiatry
62
發行號4
出版狀態已發佈 - 4月 1997

ASJC Scopus subject areas

  • 神經心理學與生理心理學
  • 神經科學 (全部)
  • 精神病學和心理健康

指紋

深入研究「Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine」主題。共同形成了獨特的指紋。

引用此